随机、盲法、阳性对照评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群接种的免疫原性和安全性的Ⅱ期临床试验
[Translation] A randomized, blinded, positive-controlled phase II clinical trial to evaluate the immunogenicity and safety of a recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
主要目的: 评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的免疫原性
次要目的: 评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的安全性
探索性目的: 评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的免疫持久性
[Translation] Primary objective: To evaluate the immunogenicity of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
Secondary objective: To evaluate the safety of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
Exploratory objective: To evaluate the immune persistence of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
单中心、随机、盲法、对照设计评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的安全性、耐受性,初步探索免疫原性的Ⅰ期临床试验
[Translation] A single-center, randomized, blinded, controlled phase I clinical trial to evaluate the safety and tolerability of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above, and to preliminarily explore the immunogenicity
主要目的:评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的安全性
探索性目的:评价重组带状疱疹疫苗(CHO细胞)在40岁及以上人群中接种的免疫原性
[Translation] Primary objective: To evaluate the safety of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
Exploratory objective: To evaluate the immunogenicity of recombinant herpes zoster vaccine (CHO cells) in people aged 40 years and above
100 Clinical Results associated with Huanuotai Biomedical Technology (Chengdu) Co., Ltd.
0 Patents (Medical) associated with Huanuotai Biomedical Technology (Chengdu) Co., Ltd.
100 Deals associated with Huanuotai Biomedical Technology (Chengdu) Co., Ltd.
100 Translational Medicine associated with Huanuotai Biomedical Technology (Chengdu) Co., Ltd.